The SABRE (Study of anastrozole with the bisphosphonate RisedronatE) study: 12-month analysis

被引：0
|
作者：
Van, Poznak C.
Hannon, R. A.
Clack, G.
Campone, M.
Mackey, J. R.
Apffelstaedt, J.
Eastell, R.
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] Site Hosp Nord Nantes, Nantes, France
[5] Univ Alberta, Edmonton, AB T6G 2M7, Canada
[6] Univ Stellenbosch, ZA-7600 Tygerberg, South Africa
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [1] The SABRE (Study of anastrozole with the bisphosphonate risedronate) study: 12-month analysis
    Eastell, R.
    Van Poznak, C.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelstaedt, J.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S113 - S113
  • [2] Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE)
    Van Poznak, C.
    Hannon, R.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelsfaedt, J.
    Eastell, R.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 147S - 147S
  • [3] The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - First results
    Van Poznak, C.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackeys, J. R.
    Apffelstaedt, J.
    Eastell, R.
    [J]. BONE, 2007, 40 (06) : S159 - S160
  • [4] First results of the SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer
    Van Poznak, C.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelstaedt, J.
    Eastell, R.
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 : S44 - S44
  • [5] The SABRE (study of anastrozole with the bisphosphonate risedronate) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - First results.
    Van Poznak, C.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelstaedt, J.
    Eastell, R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S191 - S192
  • [6] EVOLUTION Study: 12-month results
    Bosiers, Marc
    Deloose, Koen
    Callaert, Joren
    Peeters, Patrick
    Verbist, Jurgen
    van den Eynde, Wouter
    Maene, Lieven
    Beelen, Roel
    Keirse, Koen
    Wauters, Jeroen
    [J]. JOURNAL OF CARDIOVASCULAR SURGERY, 2019, 60 (04): : 490 - 495
  • [7] Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
    Ebina, K.
    Noguchi, T.
    Hirao, M.
    Hashimoto, J.
    Kaneshiro, S.
    Yukioka, M.
    Yoshikawa, H.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) : 351 - 359
  • [8] Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
    K. Ebina
    T. Noguchi
    M. Hirao
    J. Hashimoto
    S. Kaneshiro
    M. Yukioka
    H. Yoshikawa
    [J]. Osteoporosis International, 2016, 27 : 351 - 359
  • [9] 12-MONTH STUDY OF AEROSOLS BELOW 60 KM
    GAMBLING, DJ
    BARTUSEK, K
    ELFORD, WG
    [J]. JOURNAL OF ATMOSPHERIC AND TERRESTRIAL PHYSICS, 1971, 33 (09): : 1403 - &
  • [10] Comparison of galantamine and rivastigmin effects -: 12-month study
    Ignjatovièová, D
    Ignjotovic, M
    [J]. PHARMACOPSYCHIATRY, 2005, 38 (01) : 54 - 54
12345